? GENOMICS SHARED RESOURCE (GSR) The mission of the GSR is to support OSUCCC members and high-impact cancer research projects with genomics expertise, instrumentation and centralized resources to generate high-quality data. The GSR is a state- of-the-art genomics laboratory that has substantially increased capacity through expansion to shared resources at Nationwide Children?s Hospital. The GSR has the following Specific Aims: 1) sequence DNA and RNA templates using both next generation sequencing platforms (i.e. Ilumina HiSeq4000 and NovaSeq6000) and capillary Sanger sequencing and genotyping (via ABI 3730XL DNA Analyzers); 2) use sensitive molecular hybridization methods to detect and quantify RNA transcript expression levels and structures such as splicing and/or DNA copy numbers and variation, including digital (NanoString) and microarray (Affymetrix) platforms; and 3) perform polymerase chain reaction (PCR)-based amplification to detect, quantify and confirm copy number variants, single nucleotide variants, gene expression, and small insertion/deletion polymorphisms including quantitative PCR (QuantStudio 12K flex) and high-throughput digital and custom PCR assay (BiomarkHD and Juno) technologies. In 2018, the GSR partnered with the Institute for Genomic Medicine (IGM) at Nationwide Children?s Hospital (NCH) to expand our next-generation sequencing (NGS) technology services. The GSR co-Directors are Drs. Amanda Toland (MCC) and Richard Wilson (CB). The GSR provides essential genomics expertise and instrumentation to members of all five programs. During the current funding cycle, the GSR contributed to 338 publications (63 > 10 impact factor) and 94 grants from members of all five programs. We have been highly responsive to changing technology and user needs and, as a result, we now offer Sanger sample pick-up, cell line verification, and single-cell (sc) RNA sequencing. We also regularly host technology- based seminars or workshops to introduce new technology to OSUCCC members. With OSUCCC and institutional support, we have expanded our facilities to improve sequencing capabilities and to include nanofluidics liquid handlers and library preparation systems for sc-sequencing to provide state-of-the-art resolution in cancer biology and response to therapy. In the next funding cycle, the GSR will support the genomics needs of all OSU strategic priorities. Given the robust OSUCCC recruitment, demand for services and new technologies will increase. The GSR will expand its staff, instrumentation and services before capacity is reached. New services under development include isolation of circulating tumor cells for down-stream culturing and genomic profiling, purchasing an instrument and developing protocols for spatial transcriptomics, purchasing an instrument for sc-DNA sequencing, and optimizing protocols for other sc-genomics and low-input NanoString applications. The annual budget of the GSR is $2,634,443, yet the CCSG request is $231,495. As such, the GSR leverages extensive institutional support and seeks only 8.8% support from CCSG funds.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
London, Cheryl A; Acquaviva, Jaime; Smith, Donald L et al. (2018) Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors. Clin Cancer Res 24:6396-6407

Showing the most recent 10 out of 2602 publications